Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Teladoc Health Inc (TDOC) vs Thomson Reuters Corp (TRI) Price & Performance

Teladoc Health IncTrade
Thomson Reuters CorpTrade

Price performance (Past 24H)

Key statistics

Teladoc Health Inc vs Thomson Reuters Corp — how do they compare? Teladoc Health Inc trades at $9.65 (market cap $1.74B), while Thomson Reuters Corp trades at $90.5 (market cap $41.28B). The key difference: Thomson Reuters Corp is far larger — about 23.7× Teladoc Health Inc's market cap, and Thomson Reuters Corp pays a 2.75% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.

TDOCTRI
Market Cap
$1.74B$41.28B
Sector
HealthIndustrials
52-Week High
$9.72$205.54
52-Week Low
$4.47$76.55
Enterprise Value
$2.03B$43.24B
Dividend Yield
2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Teladoc Health Inc

TDOC trades at $9.71, up 2.97% with a bullish technical signal. The stock shows improving fundamentals with revenue stabilizing around $2.5B and narrowing losses. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Positive sentiment is driven by partnerships like Walmart Better Care and cost-cutting initiatives, though net margins remain negative.

The outlook suggests cautious optimism as operational improvements may drive recovery, but persistent losses and high debt pose risks. Analyst consensus is mixed with 36% buy ratings and a $9.50 price target, indicating limited upside. Investors should weigh cost-control progress against competitive pressures in telehealth.

Thomson Reuters Corp

Thomson Reuters (TRI) trades at $90.67, down 5.75% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.93% net margin and 12.63% ROE, though recent earnings showed mixed results with a Q4 2025 miss. Recent developments include a joint venture with KKR for the global print business and strategic AI implementation, positioning TRI for future growth in content and technology services.

Wall Street remains optimistic with a $129.96 consensus price target (43% upside), driven by 51.85% buy ratings. Key risks include execution of AI strategy and competitive pressures. The stock offers value with reasonable valuation multiples (P/E 27.47, P/S 5.49) and consistent dividend payments, making it attractive for long-term investors despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Teladoc Health Inc

Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.

Read more on TDOC

About Thomson Reuters Corp

Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.

Read more on TRI